ARGX
Price
$598.79
Change
+$3.60 (+0.60%)
Updated
Jul 29 closing price
Capitalization
36.82B
One day until earnings call
HALO
Price
$59.05
Change
+$1.32 (+2.29%)
Updated
Jul 29 closing price
Capitalization
7.28B
6 days until earnings call
Interact to see
Advertisement

ARGX vs HALO

Header iconARGX vs HALO Comparison
Open Charts ARGX vs HALOBanner chart's image
argenx SE
Price$598.79
Change+$3.60 (+0.60%)
Volume$263.66K
Capitalization36.82B
Halozyme Therapeutics
Price$59.05
Change+$1.32 (+2.29%)
Volume$1.47M
Capitalization7.28B
ARGX vs HALO Comparison Chart in %
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. HALO commentary
Jul 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a StrongBuy and HALO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 30, 2025
Stock price -- (ARGX: $598.79 vs. HALO: $59.05)
Brand notoriety: ARGX and HALO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 69% vs. HALO: 71%
Market capitalization -- ARGX: $36.82B vs. HALO: $7.28B
ARGX [@Biotechnology] is valued at $36.82B. HALO’s [@Biotechnology] market capitalization is $7.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $315.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileHALO’s FA Score has 1 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • HALO’s FA Score: 1 green, 4 red.
According to our system of comparison, HALO is a better buy in the long-term than ARGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 5 TA indicator(s) are bullish while HALO’s TA Score has 5 bullish TA indicator(s).

  • ARGX’s TA Score: 5 bullish, 5 bearish.
  • HALO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than ARGX.

Price Growth

ARGX (@Biotechnology) experienced а +4.82% price change this week, while HALO (@Biotechnology) price change was +2.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.71%. For the same industry, the average monthly price growth was +15.03%, and the average quarterly price growth was +41.55%.

Reported Earning Dates

ARGX is expected to report earnings on Oct 30, 2025.

HALO is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($36.8B) has a higher market cap than HALO($7.28B). ARGX has higher P/E ratio than HALO: ARGX (36.51) vs HALO (15.70). HALO YTD gains are higher at: 23.510 vs. ARGX (-2.636). HALO has higher annual earnings (EBITDA): 705M vs. ARGX (365M). ARGX has more cash in the bank: 3.1B vs. HALO (748M). ARGX has less debt than HALO: ARGX (34M) vs HALO (1.51B). ARGX has higher revenues than HALO: ARGX (2.58B) vs HALO (1.08B).
ARGXHALOARGX / HALO
Capitalization36.8B7.28B506%
EBITDA365M705M52%
Gain YTD-2.63623.510-11%
P/E Ratio36.5115.70232%
Revenue2.58B1.08B238%
Total Cash3.1B748M415%
Total Debt34M1.51B2%
FUNDAMENTALS RATINGS
ARGX vs HALO: Fundamental Ratings
ARGX
HALO
OUTLOOK RATING
1..100
145
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
2340
SMR RATING
1..100
9112
PRICE GROWTH RATING
1..100
5553
P/E GROWTH RATING
1..100
8287
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARGX's Valuation (74) in the Pharmaceuticals Other industry is in the same range as HALO (76) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

ARGX's Profit vs Risk Rating (23) in the Pharmaceuticals Other industry is in the same range as HALO (40) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for ARGX (91) in the Pharmaceuticals Other industry. This means that HALO’s stock grew significantly faster than ARGX’s over the last 12 months.

HALO's Price Growth Rating (53) in the Biotechnology industry is in the same range as ARGX (55) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to ARGX’s over the last 12 months.

ARGX's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as HALO (87) in the Biotechnology industry. This means that ARGX’s stock grew similarly to HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXHALO
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 2 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBIIX14.87N/A
N/A
Neuberger Berman International Eq I
MOSZX9.79N/A
N/A
MassMutual Overseas I
RERHX60.34N/A
N/A
American Funds EUPAC R5E
APDJX19.59N/A
N/A
Artisan International Small-Mid Advisor
COMZX29.63N/A
N/A
DWS Digital Horizons Inst

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
+0.60%
ARGNF - ARGX
55%
Loosely correlated
N/A
IONS - ARGX
44%
Loosely correlated
+0.75%
ROIV - ARGX
44%
Loosely correlated
+0.53%
GMAB - ARGX
41%
Loosely correlated
-2.12%
AXON - ARGX
40%
Loosely correlated
-1.03%
More